Combination therapy of anti-CD19 antibody and parsaclisib
Patent Information
- Application Number
- JP2023532759
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-01-11
- Filing Date
- 2021-11-30
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
が、組成物の任意の毒性または有害効果を上回るものでもある。
Smart Images

Figure 00000000_0001_ABST 
Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims priority to international application PCT / US2021 / 012982 filed on 11 January 2021 and US provisional application 63 / 119,370 filed on 30 November 2020. The contents of the prior applications are incorporated herein by reference in their entirety. [Background technology]
[0002] Non-Hodgkin lymphomas (NMOs) are the most common hematological malignancies in adults. The majority of NMOs are of B-cell origin and are associated with several different histological subtypes, resulting in varying clinical outcomes. Apart from the pathological classification of NMOs, they are also commonly classified as low-grade or high-grade lymphomas based on their clinical features. Low-grade lymphomas progress slowly and respond to treatment, but are generally considered incurable. High-grade lymphomas progress rapidly but respond to treatment and are often curable.
[0003] Diffuse large B-cell lymphoma (DLBCL) is a high-grade, most common non-Hodgkin lymphoma, accounting for one-third of all non-Hodgkin lymphomas. DLBCL patients typically present with rapidly growing lymphomas, often accompanied by focal and systemic symptoms, as well as fever, frequent night sweats, and / or weight loss. Some patients also experience extranodal symptoms (e.g., skin, liver, stomach, CNS). The current standard of care for newly diagnosed, advanced-stage DLBCL patients is the R-CHOP immunochemotherapy regimen, consisting of the anti-CD20 monoclonal antibody rituximab® and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. After first-line R-CHOP treatment, approximately 30%–40% of patients relapse or become refractory to R-CHOP, requiring further treatment. Patients who relapse or whose disease does not respond to first-line treatment (refractory patients) have a poor prognosis.
[0004] In addition to non-Hodgkin lymphoma, there are several other B-cell malignancies resulting from B-cell dysregulation. Chronic lymphocytic leukemia is an adult leukemia caused by the abnormal accumulation of B lymphocytes. In chronic lymphocytic leukemia, the malignant lymphocytes may appear normal and mature, but are unable to effectively combat infections. Chronic lymphocytic leukemia is the most common form of adult leukemia. Another type of leukemia, acute lymphocytic leukemia, is characterized by the overproduction and continuous proliferation of malignant immature white blood cells (also known as lymphoblasts) in the bone marrow. Acute lymphocytic leukemia is most common in childhood, with the peak incidence at 4-5 years of age.
Summary of the Invention
[0005] The present disclosure features a method of treating non-Hodgkin lymphoma, chronic lymphocytic leukemia or acute lymphocytic leukemia in a human subject in need of treatment by administering a therapeutically effective amount of 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof, and an antibody that binds to human CD19, where the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR) 1, VH CDR2 and VH CDR3, VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO: 6), VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO: 7), and VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO: 8), the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2 and VL CDR3, VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 9), VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO: 10), VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO: 11).
[0006] In some embodiments, the VH domain of the antibody comprises an amino acid sequence including the amino acid sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS (SEQ ID NO: 4), and the VL domain of the antibody comprises the amino acid sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 5).
[0007] In some embodiments, the antibody comprises a heavy chain and a light chain, the heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2, and the light chain comprising the amino acid sequence shown in SEQ ID NO: 3.
[0008] In some embodiments, the human subject has non-Hodgkin lymphoma (e.g., relapsed / refractory non-Hodgkin lymphoma).
[0009] In some embodiments, non-Hodgkin lymphoma is diffuse large B-cell lymphoma (e.g., relapsed / refractory diffuse large B-cell lymphoma).
[0010] In some embodiments, non-Hodgkin lymphoma is follicular lymphoma (e.g., relapsed / refractory follicular lymphoma).
[0011] In some embodiments, non-Hodgkin lymphoma is a small lymphocytic lymphoma (e.g., relapsed / refractory small lymphocytic lymphoma).
[0012] In some embodiments, non-Hodgkin lymphoma is mucosa-associated lymphoid tissue lymphoma (e.g., relapsed / refractory mucosa-associated lymphoid tissue lymphoma).
[0013] In some embodiments, non-Hodgkin lymphoma is marginal zone lymphoma (e.g., relapsed / refractory marginal zone lymphoma).
[0014] In some embodiments, non-Hodgkin lymphoma is Burkitt lymphoma (e.g., relapsed / refractory Burkitt lymphoma).
[0015] In some embodiments, non-Hodgkin lymphoma is mantle cell lymphoma (e.g., relapsed / refractory mantle cell lymphoma).
[0016] In some embodiments, the human subject has chronic lymphocytic leukemia (e.g., relapsed / refractory chronic lymphocytic leukemia).
[0017] In some embodiments, the human subject has acute lymphoblastic leukemia (e.g., relapsed / refractory acute lymphoblastic leukemia).
[0018] In some embodiments, the antibody is administered intravenously. In some embodiments, the antibody is administered intravenously at a dose of 9 mg / kg or 12 mg / kg. In some embodiments, the antibody is administered intravenously at a dose of 9 mg / kg or 12 mg / kg. In some embodiments, the antibody is administered according to the following schedule: Days 1, 4, 8, 15, and 22 of the first 28-day cycle; Days 1, 8, 15, and 22 of the second 28-day cycle; The 1st, 8th, 15th and 22nd days of the third 28-day cycle; and, It is administered intravenously at a dose of 12 mg / kg on days 1 and 15 of the fourth 28-day cycle, and on days 1 and 15 of subsequent further 28-day cycles.
[0019] In some embodiments, 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one or a pharmaceutically acceptable salt thereof is administered orally. In some embodiments, 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one or a pharmaceutically acceptable salt thereof is administered orally in doses of 1 mg, 2.5 mg, 5 mg, 10 mg, or 20 mg. In some embodiments, 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one or a pharmaceutically acceptable salt thereof is administered orally once daily in doses of 1 mg, 2.5 mg, 5 mg, 10 mg, or 20 mg.
[0020] In some embodiments, 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one or a pharmaceutically acceptable salt thereof is administered orally at a dose of 20 mg once daily from days 1 to 56, and thereafter at a dose of 2.5 mg once daily.
[0021] In some embodiments, the antibody is administered according to the following schedule: Days 1, 4, 8, 15, and 22 of the first 28-day cycle; Days 1, 8, 15, and 22 of the second 28-day cycle; The 1st, 8th, 15th and 22nd days of the third 28-day cycle; and, It is administered intravenously at a dose of 12 mg / kg according to days 1 and 15 of the fourth 28-day cycle, and on days 1 and 15 of subsequent further 28-day cycles. 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one or a pharmaceutically acceptable salt thereof is administered orally at a dose of 20 mg once daily from days 1 to 56, and thereafter at a dose of 2.5 mg once daily.
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art in which the present invention pertains. Methods and materials similar to or equivalent to those described herein may be used in the implementation or testing of the present invention, although exemplary methods and materials are described below. All publications, patent applications, patents, and other references referenced herein are incorporated in their entirety by reference. In the event of any conflict, this application, including definitions, shall prevail. The materials, methods, and examples are illustrative and not intended to be limiting.
[0023] Other features and advantages of the present invention will become apparent from the following "Modes for Carrying Out the Invention" and "Claims." [Brief explanation of the drawing]
[0024] [Figure 1A] This graph shows the synergy scores calculated using the Bliss synergy model for ADCC activity in JVM2 cells in Experiment #1, using different concentrations of tafacitamab (1:10 dilution from 0.00001 μg / ml to 1 μg / ml) and pulsacricib (0, 0.3, 1, 3, 10, or 20 μM). [Figure 1B] This graph shows the synergy scores calculated using the Bliss synergy model for ADCC activity in JVM2 cells in Experiment #2, using different concentrations of tafacitamab (1:10 dilution from 0.00001 μg / ml to 1 μg / ml) and pulsacricib (0, 0.3, 1, 3, 10, or 20 μM). [Figure 2]This graph shows the efficacy of the following treatments for inhibiting tumor growth: (1) vehicle, (2) mouse anti-CD19 antibody, (3) pulsacricib (INCB050465), and (4) mouse anti-CD19 antibody + pulsacricib ("combination"). [Figure 3] This graph shows the efficacy of the following treatments for delaying tumor growth: (1) vehicle, (2) mouse anti-CD19 antibody, (3) pulsacricib (INCB050465), and (4) mouse anti-CD19 antibody + pulsacricib ("combination"). [Modes for carrying out the invention]
[0025] The combination of an anti-CD19 antibody and the 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one or any pharmaceutically acceptable salt thereof described herein can be used to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphocytic leukemia.
[0026] Anti-CD19 antibody CD19 is widely and homogeneously expressed across various B-cell-derived hematological malignancies. CD19 can enhance B-cell receptor signaling, which is crucial for B-cell survival, and is therefore a therapeutic target for drugs aimed at treating B-cell-associated lymphomas and leukemias.
[0027] The amino acid sequence of the human CD19 protein is (SEQ ID NO: 1).
[0028] Tafacitamab is an IgG1-G2 / κ Fc-modified monoclonal antibody that targets human CD19. The constant Fc region of tafacitamab is modified to include S239D and I332E (EU index) substitutions that enhance the immune system's response to cancer cells. The modified Fc enhances antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADCP). Tafacitamab is described in U.S. Patent No. 8,524,867, which is incorporated by reference in its entirety (in U.S. Patent No. 8,524,867, the complete heavy chain of tafacitamab is SEQ ID NO: 87, and the complete light chain of tafacitamab is SEQ ID NO: 106).
[0029] The amino acid sequences of the heavy and light chains of tafacitamab are listed below. The complementarity-determining regions (CDRs) 1, 2, and 3 of the variable heavy (VH) and variable light (VL) domains are shown in order from the N-terminus to the C-terminus of the mature VL and VH sequences, both underlined and in bold. The variable region is underlined. The antibody consisting of the heavy chain (SEQ ID NO: 2) and light chain (SEQ ID NO: 3) listed below is referred to as tafacitamab. Tafacitamab heavy chain: [ka] Tafacitamab light chain: [ka]
[0030] The variable weight (VH) domain of tafacitamab has the following amino acid sequence. [ka]
[0031] The variable light (VL) domain of tafacitamab has the following amino acid sequence. [ka]
[0032] The amino acid sequence of the VH CDR of tafacitamab is listed below. VH CDR1:SYVMH (Sequence ID 6), VH CDR2:NPYNDG (Sequence ID 7) and VH CDR3:GTYYYGTRVFDY (Sequence ID 8).
[0033] The amino acid sequence of the tafacitamab VL CDR is listed below. VL CDR1:RSSKSLQNVNGNTYLY (Sequence ID 9), VL CDR2:RMSNLNS(SEQ ID NO: 10) and VL CDR3:MQHLEYPIT (Sequence ID 11).
[0034] In certain embodiments, the anti-CD19 antibody comprises human heavy chain and light chain constant regions. In certain embodiments, the heavy chain constant region comprises a CH1 domain and a hinge region. In some embodiments, the heavy chain constant region comprises a CH2 domain. In some embodiments, the heavy chain constant region comprises a CH3 domain. In some embodiments, the heavy chain constant region comprises CH1, CH2, and CH3 domains. If the heavy chain constant region includes substitutions, such substitutions modify the properties of the antibody (e.g., increasing or decreasing one or more of the following: Fc receptor binding, antibody glycosylation, number of cysteine residues, effector cell function, or complement function). In certain embodiments, the antibody is an IgG antibody. In certain embodiments, the antibody is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
[0035] Antibodies such as tafacitamab can be produced, for example, by preparing and expressing synthetic genes encoding the listed amino acid sequences, or by mutating human germline genes to provide genes encoding the listed amino acid sequences. Furthermore, this antibody and other anti-CD19 antibodies can be obtained, for example, using one or more of the following methods.
[0036] Humanized antibodies can be produced by replacing sequences in the Fv variable region, which are not directly involved in antigen binding, with equivalent sequences derived from the human Fv variable region. Common methods for producing humanized antibodies are provided by Morrison, SL, Science, 229:1202-1207 (1985), Oi et al., BioTechniques, 4:214 (1986), and U.S. Patents 5,585,089, 5,693,761, 5,693,762, 5,859,205, and 6,407,213. These methods involve isolating, manipulating, and expressing a nucleic acid sequence encoding all or part of the immunoglobulin Fv variable region from at least one of the heavy or light chains. Sources of such nucleic acids are well known to those skilled in the art and can be obtained, for example, from hybridomas producing antibodies against a given target, from germline immunoglobulin genes, or from synthetic constructs, as described above. Next, recombinant DNA encoding a humanized antibody can be cloned into a suitable expression vector.
[0037] For example, human germline sequences are disclosed in Tomlinson, IA et al., J. Mol. Biol., 227:776-798 (1992); Cook, GP et al., Immunol. Today, 16: 237-242 (1995); Chothia, D. et al., J. Mol. Bio. 227:799-817 (1992); and Tomlinson et al., EMBO J., 14:4628-4638 (1995). The V BASE directory provides a comprehensive directory of human immunoglobulin variable region sequences (Tomlinson, IA et al. MRC Centre for Protein Engineering, Cambridge, UK). These sequences can be used, for example, as a source of human sequences for framework regions and CDRs. Consensus human framework regions can also be used, for example, as described in U.S. Patent No. 6,300,064.
[0038] Other methods for humanizing antibodies may also be used. For example, other methods can describe the three-dimensional structure of the antibody, the framework position in three-dimensional proximity to the binding determinant, and the immunogenic peptide sequence. See, for example, WO90 / 07861, U.S. Patents 5,693,762, 5,693,761, 5,585,089, 5,530,101 and 6,407,213, and Tempest et al. (1991) Biotechnology 9:266-271. Yet another method, referred to as "humanization," is described, for example, U.S. Patent 2005-008625.
[0039] The antibody may contain a human Fc region, for example, a wild-type Fc region or an Fc region containing one or more modifications. In one embodiment, the constant region is modified, for example, the human IgG1 constant region is mutated to include the S239D and / or I332E substitution. The antibody may also have mutations that stabilize the disulfide bond between the two heavy chains of the immunoglobulin, such as a mutation in the hinge region of IgG4 (e.g., Angal et al. (1993) Mol. Immunol. 30:105-08), as disclosed in the Art. See, for example, U.S. Patent No. 2005 / 0037000.
[0040] Anti-CD19 antibodies may be in the form of full-length antibodies or in the form of low molecular weight forms of anti-CD19 antibodies, such as Fab, Fab', F(ab')2, Fv, Fd, dAb, scFv, and sc(Fv)2 (e.g., biologically active antibody fragments or minibodies). Other anti-CD19 antibodies included in this disclosure include single-domain antibodies (sdAb) containing a single variable chain such as VH or VL, or a biologically active fragment thereof. See, for example, Moller et al., J. Biol. Chem., 285(49): 38348-38361 (2010); Harmsen et al., Appl. Microbiol. Biotechnol., 77(1):13-22 (2007); US 2005 / 0079574 and Davies et al. (1996) Protein Eng., 9(6):531-7. Like all antibodies, sdAbs can selectively bind to specific antigens. With a molecular weight of only 12-15 kDa, sdAbs are much smaller than typical antibodies, and even smaller than Fab fragments and single-stranded variable fragments.
[0041] This specification provides compositions comprising an anti-CD19 antibody or its antigen-binding fragment and a mixture of one or more acidic variants, for example, the amount of acidic variant(s) being about 80%, 70%, 60%, 60%, 50%, 40%, 30%, 30%, 20%, 10%, 5%, or less than 1%. Also provided are compositions comprising an anti-CD19 antibody or its antigen-binding fragment containing at least one deamidation site, with a pH of about 5.0 to about 6.5, for example, such that at least about 90% of the anti-CD19 antibody is not deamidated (i.e., less than about 10% of the antibody is deamidated). In certain embodiments, less than about 5%, 3%, 2%, or 1% of the antibody is deamidated. The pH may be 5.0 to 6.0, such as 5.5 or 6.0. In certain embodiments, the pH of the composition is 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5.
[0042] An "acidic mutant" is a variant of the target polypeptide that is more acidic than the target polypeptide (for example, determined by cation exchange chromatography). An example of an acidic mutant is a deamidation mutant.
[0043] A "deamidation" mutant of a polypeptide molecule is a polypeptide in which one or more asparagine residues of the original polypeptide are converted to aspartic acid, that is, the neutral amide side chain is converted to a residue with overall acidic properties.
[0044] As used herein, the term “mixture” refers to a composition comprising an anti-CD19 antibody or its antigen-binding fragment, and means the presence of both the desired anti-CD19 antibody, its antigen-binding fragment, and one or more acidic variants thereof. The acidic variants may primarily consist of a deamidated anti-CD19 antibody, along with small amounts of other acidic variants.
[0045] In certain embodiments, the binding affinity (K) of the antibody mutated to eliminate deamidation is D ), On Rate (K D On) and / or Off Rate (K D The off-label (off) antibody is similar to that of the wild-type antibody, for example, with differences of approximately 5x, 2x, 1x (100%), 50%, 30%, 20%, 10%, 5%, 3%, 2%, or less than 1%.
[0046] bispecific antibody In certain embodiments, the anti-CD19 antibody or its antigen-binding fragment described herein is present in a bispecific antibody. A bispecific antibody is an antibody that has binding specificity to at least two different epitopes. An exemplary bispecific antibody may bind to two different epitopes of the CD19 protein. Other such antibodies may combine the CD19 binding site with a binding site of another protein. Bispecific antibodies can be prepared as full-length antibodies or in their lower molecular weight forms (e.g., F(ab')2 bispecific antibody, sc(Fv)2 bispecific antibody, diabody bispecific antibody).
[0047] Conventional production of full-length bispecific antibodies is based on the co-expression of two immunoglobulin heavy-light chain pairs, where these two chains have different specificities (Millstein et al., Nature, 305:537-539 (1983)). In a different approach, an antibody variable domain with the desired binding specificity is fused to the immunoglobulin constant domain sequence. The immunoglobulin heavy-chain fusion, and optionally the DNA encoding the immunoglobulin light chain, is inserted into separate expression vectors and co-transfected into suitable host cells. This provides greater flexibility in adjusting the ratio of the three polypeptide fragments. However, if high yields are obtained by expressing at least two polypeptide chains in equal ratios, it is possible to insert the coding sequences of two or all three polypeptide chains into a single expression vector.
[0048] Alternatively, the interface between a pair of antibody molecules may be manipulated according to another approach described in U.S. Patent No. 5,731,168 to maximize the proportion of heterodimers recovered from the recombinant cell culture. A preferred interface is C H3 This method involves at least a portion of the domain. In this method, one or more smaller amino acid side chains originating from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). By replacing the larger amino acid side chains with smaller amino acid side chains (e.g., alanine or threonine), a compensatory "cavity" of the same or similar size as the larger side chain(s) is created on the interface of the second antibody molecule. This provides a mechanism for increasing the yield of heterodimers compared to other undesirable end products such as homodimers.
[0049] Examples of bispecific antibodies include crosslinked or "heteroconjugated" antibodies. For example, in a heteroconjugated antibody, one antibody may be coupled to avidin and the other to biotin. Heteroconjugated antibodies can be prepared using any simple crosslinking method.
[0050] The "Diabody" technology provides an alternative mechanism for producing bispecific antibody fragments. These fragments contain a VH domain connected to a VL domain by a linker that is too short to allow pairing between two domains on the same chain. Thus, the VH and VL domains of one fragment are paired with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites.
[0051] Multivalent antibodies In certain embodiments, the anti-CD19 antibody or its antigen-binding fragment described herein is present in a multivalent antibody. A multivalent antibody may be translocated (and / or catabolized) more quickly than a bivalent antibody by cells expressing the antigen to which the antibody binds. The antibodies provided herein may also be multivalent antibodies (e.g., tetravalent antibodies) having three or more antigen-binding sites, which can be readily produced by recombinant expression of the nucleic acid encoding the antibody polypeptide chain. A multivalent antibody may include a dimerization domain and three or more antigen-binding sites. An exemplary dimerization domain includes (or consists of) an Fc region or a hinge region. A multivalent antibody may include (or consist of) three to about eight (e.g., four) antigen-binding sites. A multivalent antibody optionally includes at least one polypeptide chain (e.g., at least two polypeptide chains), which may include two or more variable domains. For example, the polypeptide chain may be VD1-(X1) n -VD2-(X2) n -May include Fc, where VD1 is the first variable domain, VD2 is the second variable domain, Fc is a polypeptide chain of the Fc region, X1 and X2 represent amino acids or peptide spacers, and n is 0 or 1.
[0052] Conjugate Antibody The antibodies disclosed herein include polymers (e.g., polyethylene glycol (PEG), polyethyleneimine (PEI) modified with PEG (PEI-PEG), polyglutamic acid (PGA) (N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer), hyaluronic acid, radioactive materials (e.g., 90 Y, 131 I) Conjugate antibodies may be bound to a variety of molecules, including macromolecules such as fluorescent substances, luminescent substances, haptens, enzymes, metal chelates, drugs, and toxins (e.g., calchaemycin, Pseudomonas exotoxin A, lysine (e.g., deglycosylated lysine A chain)).
[0053] In one embodiment, to improve the cytotoxic effect of anti-CD19 antibodies and consequently enhance their therapeutic efficacy, antibodies are conjugated with highly toxic substances, including radioisotopes and cytotoxic agents. These conjugates can selectively deliver a toxic load to target sites (i.e., cells expressing the antigen recognized by the antibody), while cells not recognized by the antibody are spared. To minimize toxicity, conjugates are generally engineered based on molecules with short serum half-lives (hence the use of mouse sequences and IgG3 or IgG4 isotypes).
[0054] In certain embodiments, an anti-CD19 antibody or its antigen-binding fragment is modified with a portion that improves its stabilization and / or retention in circulation, for example, by at least 1.5, 2, 5, 10, or 50 times, in blood, serum, or other tissues. For example, an anti-CD19 antibody or its antigen-binding fragment can associate (e.g., conjugate) with a polymer, such as a substantially non-antigenic polymer, such as a polyalkylene oxide or polyethylene oxide. Suitable polymers vary substantially by weight. Polymers having a molecular number-average weight in the range of about 200 to about 35,000 daltons (or about 1,000 to about 15,000, and 2,000 to about 12,500) can be used. For example, an anti-CD19 antibody or its antigen-binding fragment can be conjugated with a water-soluble polymer, such as a hydrophilic polyvinyl polymer, such as polyvinyl alcohol or polyvinylpyrrolidone. Examples of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycol, polyoxyethylene polyols, copolymers thereof, and block copolymers thereof, provided that the water solubility of the block copolymers is maintained. Further useful polymers include polyoxyalkylenes such as polyoxyethylene and polyoxypropylene, as well as block copolymers of polyoxyethylene and polyoxypropylene, polymethacrylates, carbomers, and branched or unbranched polysaccharides.
[0055] The conjugate antibodies described above can be prepared by chemically modifying the antibodies or their low molecular weight forms described herein. Methods for modifying antibodies are well known in the art (e.g., U.S. Patents 5,057,313 and 5,156,840).
[0056] Methods for producing antibodies Antibodies can be produced in bacteria or eukaryotic cells. Some antibodies, such as Fab', can be produced in bacterial cells, e.g., E. coli cells. Antibodies can also be produced in eukaryotic cells such as transformed cell lines (e.g., CHO, 293E, COS). In addition, antibodies (e.g., scFv') can be expressed in yeast cells such as Pichia (e.g., Powers et al., J Immunol Methods. 251:123-35 (2001)), Hanseula, or Saccharomyces. To produce the antibody of interest, the polynucleotide encoding the antibody is constructed, introduced into an expression vector, and then expressed in a suitable host cell. Using standard molecular biology techniques, recombinant expression vectors are prepared, host cells are transfected, transformants are selected, the host cells are cultured, and the antibodies are recovered.
[0057] When antibodies are expressed in bacterial cells (e.g., E. coli), the expression vector should have characteristics that allow for amplification of the vector within the bacterial cell. Furthermore, when using E. coli such as JM109, DH5α, HB101, or XL1-Blue as the host, the vector must have a promoter, such as the lacZ promoter (Ward et al., 341:544-546 (1989)), the araB promoter (Better et al., Science, 240:1041-1043 (1988)), or a T7 promoter that can enable efficient expression in E. coli. Examples of such vectors include, for example, the M13 series vectors, the pUC series vectors, pBR322, pBluescript, pCR-Script, pGEX-5X-1 (Pharmacia), "QIAexpress system" (QIAGEN), pEGFP, and pET (when this expression vector is used, the host is preferably BL21 expressing T7 RNA polymerase). The expression vector may contain a signal sequence for antibody secretion. For production into the peripheral plasma of E. coli, a pelB signal sequence (Lei et al., The sequence J. Bacteriol., 169:4379 (1987) may be used as the signal sequence for antibody secretion. For bacterial expression, the expression vector may be introduced into bacterial cells using the calcium chloride method or electroporation method.
[0058] When antibodies are expressed in animal cells such as CHO, COS, and NIH3T3 cells, the expression vector includes a promoter necessary for expression in these cells, such as the SV40 promoter (Mulligan et al., Nature, 277:108 (1979)), the MMLV-LTR promoter, the EF1α promoter (Mizushima et al., Nucleic Acids Res., 18:5322 (1990)), or the CMV promoter. In addition to the nucleic acid sequence encoding the immunoglobulin or its domain, the recombinant expression vector may contain additional sequences, such as sequences that regulate vector replication in host cells (e.g., origin of replication) and selection marker genes. Selection marker genes can facilitate the selection of host cells into which the vector has been introduced (see, for example, U.S. Patents 4,399,216, 4,634,665, and 5,179,017). For example, selection marker genes typically confer resistance to drugs such as G418, hygromycin, and methotrexate to host cells into which the vector has been introduced. Examples of vectors containing selection markers include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.
[0059] In one embodiment, the antibody is produced in mammalian cells. Exemplary mammalian host cells for antibody expression include Chinese hamster ovary (CHO cells) (including dhfr-CHO cells described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, and used with a DHFR selection marker, for example, as described in Kaufman and Sharp (1982) Mol. Biol. 159:601 621), human embryonic kidney 293 cells (e.g., 293, 293E, 293T), COS cells, NIH3T3 cells, lymphocyte cell lines, for example, NS0 myeloma cells and SP2 cells, as well as cells derived from transgenic animals, such as transgenic mammals.
[0060] In an exemplary system for antibody expression, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain of an anti-CD19 antibody (e.g., tafasitamab) is transfected into dhfr - CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy chain and light chain genes are operably linked to enhancer / promoter regulatory elements (e.g., those derived from SV40, CMV, adenovirus, such as the CMV enhancer / AdMLP promoter regulatory element or the SV40 enhancer / AdMLP promoter regulatory element), driving high-level transcription of the genes. The recombinant expression vector also carries the DHFR gene, which enables the selection of CHO cells transfected with the vector using methotrexate selection / amplification. The selected transformed host cells are cultured to enable the expression of the antibody heavy chain and light chain, and the antibody is recovered from the culture medium.
[0061] Antibodies can also be produced by transgenic animals. For example, U.S. Patent No. 5,849,992 describes a method for expressing an antibody in the mammary gland of a transgenic mammal. The transgene is constructed to include a milk-specific promoter, a nucleic acid encoding the antibody of interest, and a signal sequence for secretion. Milk produced by female such transgenic mammals contains the antibody of interest secreted therein. The antibody can be purified from the milk or can be used directly for some applications. Animals containing one or more of the nucleic acids described herein are also provided.
[0062] The antibodies of this disclosure can be isolated from inside or outside host cells (e.g., culture medium) and purified as substantially pure and homogeneous antibodies. Isolation and purification methods commonly used for antibody purification may be used for the isolation and purification of antibodies, and are not limited to any particular method. Antibodies can be isolated and purified, for example, by appropriately selecting and combining column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, and recrystallization. Chromatographic methods include, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reversed-phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). Chromatography can be performed using liquid-phase chromatography such as HPLC and FPLC. Examples of columns used in affinity chromatography include protein A columns and protein G columns. Examples of columns using Protein A columns include Hyper D, POROS, and Sepharose FF (GE Healthcare Biosciences). This disclosure also includes antibodies highly purified using these purification methods.
[0063] Antibody drug composition and administration The anti-CD19 antibodies or antigen-binding fragments described herein may be formulated as pharmaceutical compositions for administration to a subject, for example, to treat the disorders described herein. Typically, the pharmaceutical compositions include a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” includes any physiologically compatible solvent, dispersion medium, coating, antimicrobial and antifungal agent, isotonic agent and absorption retarder, etc. The composition may include a pharmaceutically acceptable salt, such as an acid-added salt or a base-added salt (see, for example, Berge, SM, et al. (1977) J. Pharm. Sci. 66:1-19).
[0064] Pharmaceutical formulation is a well-established technology, for example, Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20 th ed., Lippincott, Williams & Wilkins (2000) (ISBN: 0683306472); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7 th Ed., Lippincott Williams & Wilkins Publishers (1999) (ISBN: 0683305727); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3 rd Further details are provided in the ed. (2000) (ISBN: 091733096X).
[0065] Anti-CD19 antibodies or their antigen-binding fragments can be administered by various means to subjects, such as human subjects, who require them. In many applications, the route of administration is one of the following: intravenous injection or infusion (IV), subcutaneous injection (SC), intraperitoneal injection (IP), or intramuscular injection. Intra-articular delivery is also possible. Other methods of parenteral administration can also be used. Examples of such modes include intra-arterial, subarachnoid, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, intra-articular, subcapsular, subarachnoid, intraspinal, and epidural and intrasternal injections. In some cases, administration may be oral.
[0066] The route and / or mode of administration of antibodies or their antigen-binding fragments may also be tailored to individual cases, for example, by monitoring the target organism, for example, by using tomography to visualize tumors.
[0067] Antibodies or their antigen-binding fragments may be administered as a fixed dose or in doses of mg / kg patient body weight. The dose may also be selected to reduce or avoid antibody production against the anti-CD19 antibody. The dosing regimen is adjusted to provide a desired response (e.g., therapeutic response) or combination therapeutic effect. Generally, the dose of anti-CD19 antibody may be used to deliver the drug to a subject in an amount available to the organism. For example, doses ranging from about 9 mg / kg to about 12 mg / kg may be administered. In certain embodiments, subjects requiring treatment with anti-CD19 antibody are administered the antibody in doses of about 9 mg / kg to 12 mg / kg. With respect to dose or dosage, the term “about” is intended to indicate a range of ±10% of the listed doses, for example, a dose of about 3 mg / kg being 2.7 mg / kg patient body weight to 3.3 mg / kg patient body weight.
[0068] As used herein, the terms "dosage unit form" or "fixed dose" or "uniform dose" refer to physically separate units suitable as a unit dosage for treating a subject, each unit containing a predetermined amount of the active compound calculated to produce the desired therapeutic effect in relation to the required pharmaceutical carrier and, optionally, in relation to other agents. Single or multiple doses may be administered. Alternatively, the antibody may be administered via serial infusion. Exemplary fixed doses include approximately 675 mg, approximately 900 mg, approximately 1200 mg, and approximately 1800 mg. With respect to dose or dosage, the term "approximately" is intended to indicate a range of ±10% of the listed doses, for example, such that a dose of approximately 375 mg is between 337.5 mg and 412.5 mg.
[0069] The dose of the anti-CD19 antibody or its antigen-binding fragment can be administered at regular intervals over a sufficient period (course of treatment) to include, for example, at least two, three, five, ten, or more doses, such as once or twice daily, or about one to four times per week (e.g., at least twice per week), or weekly, every other week (once every two weeks), every three weeks, or monthly, for example, about once to twelve weeks. Factors that may influence the dose and timing required to effectively treat the subject include, for example, the severity of the disease or disorder, the formulation, the route of delivery, previous treatments, the subject's general health and / or age, and other pre-existing diseases. Furthermore, treatment of the subject with a therapeutically effective amount of the compound may include a single treatment or, preferably, a series of treatments.
[0070] An exemplary dosing regimen includes administering an anti-CD19 antibody or its antigen-binding fragment at a fixed dose of approximately 675 mg once every two weeks. Another exemplary dosing regimen includes administering an anti-CD19 antibody or its antigen-binding fragment at a fixed dose of approximately 900 mg once every two weeks. Yet another exemplary dosing regimen includes administering an anti-CD19 antibody or its antigen-binding fragment at a fixed dose of approximately 1200 mg once every two weeks.
[0071] An example medication plan based on weight is as follows: Days 1, 4, 8, 15, and 22 of the first 28-day cycle; Days 1, 8, 15, and 22 of the second 28-day cycle; The 1st, 8th, 15th and 22nd days of the third 28-day cycle; and, This involves administering an anti-CD19 antibody or its antigen-binding fragment at a dose of approximately 12 mg / kg once every two weeks, according to the 1st and 15th days of the fourth 28-day cycle, and the 1st and 15th days of subsequent further 28-day cycles.
[0072] A pharmaceutical composition may contain a “therapeutic dose” of the anti-CD19 antibody or its antigen-binding fragment described herein. Such a dose may be determined based on the effect of the administered drug or, if two or more drugs are used, the combined effect of the drugs. The “therapeutic dose” of a drug may also vary due to factors such as the individual’s disease state, age, sex, and weight, as well as the compound’s ability to elicit a desired response in the individual, e.g., improvement of at least one disorder parameter or improvement of symptoms of at least one disorder. The therapeutic dose is also such that the therapeutically beneficial effect outweighs any toxic or adverse effects of the composition.
[0073] Pulsacryl This application provides a method for administering 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one ("Palsacricib" or "INCB050465") or a pharmaceutically acceptable salt thereof, in combination with an anti-CD19 antibody or an antigen-binding fragment thereof.
[0074] In some embodiments, the administered compound is (S)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one; (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one; (S)-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one; or (R)-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one; or their pharmaceutically acceptable salts.
[0075] In some embodiments, the compound administered is a pharmaceutically acceptable salt of 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one.
[0076] In some embodiments, the administered compound is (S)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one; (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one; (S)-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one; or Selected from pharmaceutically acceptable salts of (R)-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one.
[0077] In some embodiments, the compound administered is a pharmaceutically acceptable salt of (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one.
[0078] In some embodiments, the compound administered is (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one hydrochloride.
[0079] In some embodiments, the salt is (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidine-2-one in a 1:1 stoichiometric ratio to hydrochloric acid.
[0080] In some embodiments, the salt is crystalline.
[0081] In some embodiments, the hydrochloride of 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one is selected from at least 1, 2, 3 with respect to 2θ, approximately 11.3°, approximately 16.4°, approximately 21.0°, approximately 23.0°, approximately 28.1°, approximately 31.2° and approximately 32.8°. Having four or five XRPD peaks; at least two XRPD peaks selected from approximately 11.3°, 16.4°, 21.0°, 23.0°, 28.1°, 31.2°, and 32.8° with respect to 2θ; and at least three XRPD peaks selected from approximately 11.3°, 16.4°, 21.0°, 23.0°, 28.1°, 31.2°, and 32.8° with respect to 2θ. In some embodiments, the hydrochloride salt of 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one has at least four XRPD peaks selected from approximately 11.3°, approximately 16.4°, approximately 21.0°, approximately 23.0°, approximately 28.1°, approximately 31.2°, and approximately 32.8° with respect to 2θ. In some embodiments, the hydrochloride salt of 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one has all the listed XRPD peaks with respect to 2θ at approximately 11.3°, approximately 16.4°, approximately 21.0°, approximately 23.0°, approximately 28.1°, approximately 31.2° and approximately 32.8°. In some embodiments, the hydrochloride salt of 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidine-2-one has a DSC thermogram with an endothermic peak at approximately 207°C.
[0082] The compounds described herein, including their salts, can be prepared using known organic synthesis techniques and can be synthesized according to any of a number of possible synthetic routes. In some embodiments, the compounds can be prepared as described in U.S. Patents 9,199,982, 9,932,341 and 10,336,759, each of which is incorporated herein by reference in its entirety.
[0083] The reactions for preparing the compounds described herein can be carried out in suitable solvents that can be readily selected by those skilled in the art of organic synthesis. Suitable solvents can be substantially inactive with the starting materials (reactants), intermediates, or products at the temperature in which the reaction is carried out, for example, in the range from the freezing temperature to the boiling temperature of the solvent. A given reaction can be carried out in one solvent or a mixture of two or more solvents. Depending on the specific reaction step, a solvent suitable for that particular reaction step can be selected by those skilled in the art.
[0084] The preparation of the compounds described herein may involve the protection and deprotection of various chemical groups. The need for protection and deprotection, as well as the selection of appropriate protecting groups, can be readily determined by those skilled in the art. The chemical properties of protecting groups can be found, for example, in TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.
[0085] The reaction can be monitored according to any preferred method known in the art. For example, the formation of the product can be monitored by nuclear magnetic resonance spectroscopy (e.g., 1 H or 13C) The compounds can be monitored by spectroscopic means such as infrared spectroscopy, spectrophotometric methods (e.g., ultraviolet-visible), mass spectrometry, or chromatographic methods such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin-layer chromatography (TLC). Compounds can be purified by those skilled in the art by various methods, including high-performance liquid chromatography (HPLC) ("Preparative LC-MS Purification: Improved Compound Specific Method Optimization" Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs J. Combi. Chem. 2004, 6(6), 874-883, which is incorporated herein by reference in its entirety) and normal-phase silica chromatography.
[0086] In some embodiments, the salts and compounds described herein are substantially isolated. "Substantially isolated" means that the salt or compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial isolation may include, for example, a composition in which the salts described herein are concentrated. Substantial isolation may include a composition containing at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the salts described herein, or the salts thereof. Methods for isolating compounds and their salts are commonplace in the art.
[0087] Labeled compounds and assay methods The methods of the present disclosure further include the use of isotope-labeled pulsacrisib or a pharmaceutically acceptable salt thereof. An “isotope-labeled” or “radiolabeled” compound is a compound of the present disclosure in which one or more atoms are replaced, i.e., substituted, with atoms having atomic weights or mass numbers different from those normally found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated into the compounds of the present disclosure include: 2 H (deuterium is also written as D), 3 H (Tritium is also written as T), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 131 Examples include, but are not limited to, I. For example, one or more hydrogen atoms in the compounds of the Disclosure may be replaced by deuterium atoms (for example, one or more hydrogen atoms in the alkyl group of the compound may optionally be replaced by deuterium atoms, e.g., -CH3 is replaced by -CD3).
[0088] One or more constituent atoms of the compounds presented herein may be replaced or substituted with isotopes of atoms of natural or unnatural abundance. In some embodiments, the compounds contain at least one deuterium atom. In some embodiments, the compounds contain two or more deuterium atoms. In some embodiments, the compounds contain one to two, one to three, one to four, one to five, or one to six deuterium atoms. In some embodiments, all hydrogen atoms in the compound can be replaced, i.e., substituted, with deuterium atoms.
[0089] In some embodiments, the 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms bonded to the carbon atom of any A substituent are each optionally replaced by a deuterium atom.
[0090] Synthetic methods for incorporating isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, NY, Appleton-Century-Crofts, 1971; The Renaissance of H / D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopic-labeled compounds can be used in a variety of experiments, such as NMR spectroscopy, metabolic experiments, and / or assays.
[0091] Substitution with heavier isotopes, such as deuterium, can lead to certain therapeutic benefits stemming from increased metabolic stability, such as an extended in vivo half-life or reduced dosage requirements, and thus, in some cases, can be obtained (see, e.g., A. Kerekes et. al. J. Med. Chem. 2011, 54, 201-210; R. Xu et. al. J. Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolic sites may result in one or more therapeutic benefits.
[0092] The radionuclides incorporated into the radiolabeled compound depend on the specific application of that radiolabeled compound. For example, in the case of in vitro PI3K labeling and competitive assays, 3 H, 14 C,82 Br, 125 I, 131 I or 35 Compounds incorporating S may be useful. In imaging applications using radiation, 11 C, 18 F, 125 I, 123 I, 124 I, 131 I, 75 Br, 76 Br or 77 Br may be useful.
[0093] A “radiolabeled” or “labeled compound” is understood to be a compound incorporating at least one radionuclide. In some embodiments, the radionuclide is: 3 H, 14 C, 125 I, 35 S and 82 Selected from the group consisting of Br.
[0094] This disclosure may further include synthetic methods for incorporating radioisotopes into the compounds of this disclosure. Synthetic methods for incorporating radioisotopes into organic compounds are known in the art, and those skilled in the art will readily recognize methods applicable to the compounds of this disclosure.
[0095] Prescription and administration of palsacrisib formulations Pulsacricib or pharmaceutically acceptable salts thereof may be administered in the form of pharmaceutical compositions. These compositions may be prepared in forms well known in the pharmaceutical field and may be administered by various routes depending on whether topical or systemic treatment is desired and the area to be treated. Administration may be topical (including transdermal, epidermal, ocular, and mucosal delivery, including intranasal, vaginal, and rectal delivery), transpulmonary (e.g., by inhalation or blowing of powders or aerosols, including by nebulizer; intratracheal or nasal), oral, or parenteral. Parenteral administration may include intravenous, intra-arterial, subcutaneous, intraperitoneal, intramuscular, or by injection or infusion, or intracranial, e.g., intrathecal or intraventricular administration. Parenteral administration may be in the form of a single bolus dose or, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous bases, powder bases, or oily bases, thickeners, etc., are either essential or desirable.
[0096] The Disclosure also includes pharmaceutical compositions comprising pulsacricib or a pharmaceutically acceptable salt thereof as an active ingredient in combination with one or more pharmaceutically acceptable carriers (additives). In some embodiments, the compositions are suitable for topical administration. When preparing the compositions of the Disclosure, the active ingredient is typically mixed with an additive and diluted by the additive, or encapsulated in such a carrier, for example, in the form of a capsule, sachet, paper, or other container. If the additive functions as a diluent, it may be a solid, semi-solid, or liquid material that functions as a vehicle, carrier, or medium for the active ingredient. Thus, the compositions may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solid or liquid media), for example, ointments, soft and hard gelatin capsules, suppositories, sterile injection solutions, and sterile packaging powders containing up to 10% by weight of the active compound.
[0097] When preparing a formulation, the active compound may be ground to provide an appropriate particle size before being combined with other components. If the active compound is substantially insoluble, it may be ground to a particle size of less than 200 mesh. If the active compound is substantially water-soluble, the particle size can be adjusted by grinding to, for example, about 40 mesh, to provide a substantially uniform distribution in the formulation.
[0098] The compounds of this disclosure may be ground using known grinding procedures, such as wet grinding, to obtain particle sizes suitable for tablet formation and other formulation types. Finely divided (nanoparticle) preparations of the compounds of this disclosure may be prepared by processes known in the art, see, for example, the disclosure of International Application WO2002 / 000196.
[0099] Some examples of suitable additives include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methylcellulose. The formulation may further include lubricants such as talc, magnesium stearate, and mineral oil, wetting agents, emulsifiers, and suspending agents, preservatives such as methyl benzoate and propyl hydroxybenzoate, sweeteners, and flavorings. The compositions of the present invention can be formulated to provide rapid, sustained, or delayed release of the active ingredient after administration to a patient using procedures known in the art.
[0100] The composition may be formulated in unit dosage forms. The term "unit dosage form" refers to a physically distinct unit suitable as a unit dose for human subjects and other mammals, each unit containing a predetermined amount of active substance calculated to produce the desired therapeutic effect in relation to a suitable pharmaceutical additive.
[0101] To prepare solid compositions such as tablets, the main active ingredient is mixed with pharmaceutical additives to form a solid preliminary formulation composition containing a homogeneous mixture of the compounds of the present invention. When these preliminary formulation compositions are referred to as homogeneous, the active ingredient is typically uniformly dispersed throughout the composition, thereby allowing the composition to be easily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules. This solid preliminary formulation is then subdivided into unit dosage forms.
[0102] The tablets or pills of this disclosure may be coated or otherwise formulated to provide a dosage form that offers the benefit of long-term action. For example, the tablets or pills may contain internal and external dose components, the latter in the form of an envelope over the former. The two components may be separated by an enteric coating that resists disintegration in the stomach and allows the internal component to pass intact into the duodenum or delays its release. A variety of substances, including numerous polymer acids, as well as mixtures of polymer acids with substances such as shellac, cetyl alcohol, and cellulose acetate, can be used as such enteric coatings or coatings.
[0103] Liquid forms in which the compounds and compositions of the present invention may be incorporated for oral or injectable administration include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, and emulsions flavored with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
[0104] Compositions for inhalation or inhalation include liquids and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable additives as described above. In some embodiments, compositions are administered by oral or nasal respiratory pathways for topical or systemic effects. Compositions may be sprayed using an inert gas. The sprayed solution may be inhaled directly from a spraying device, or the spraying device may be attached to a face mask, tent, or intermittent positive pressure (PPP) respiration device. Compositions in solution, suspension, or powder form may be administered orally or nasally from a device that delivers the formulation in an appropriate manner.
[0105] The amount of compound or composition administered to a patient will vary depending on what is being administered, the purpose of administration (such as prevention or treatment), the patient's condition, and the method of administration. For therapeutic use, a composition may be administered to a patient already suffering from the disease in an amount sufficient to cure or at least partially prevent the symptoms of the disease and its complications. The effective dose depends on the disease condition being treated, as well as the judgment of the attending physician based on factors such as the severity of the disease, the patient's age, weight, and general condition.
[0106] The compositions administered to the patient may be in the form of the pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques or aseptically filtered. Aqueous solutions may be packaged for immediate use or lyophilized, and the lyophilized preparations may be combined with a sterile aqueous carrier before administration. The pH of the compound preparations will typically be 3 to 11, more preferably 5 to 9, and most preferably 7 to 8. It will be understood that formulations of pharmaceutical salts may be obtained by using certain aforementioned additives, carriers, or stabilizers.
[0107] The therapeutic dose of the compounds disclosed herein may vary depending, for example, the specific use in which the treatment is performed, the method of administration of the compound, the patient's health and symptoms, and the judgment of the prescribing physician. The proportion or concentration of the compounds disclosed herein in a pharmaceutical composition may vary depending on several factors, including the dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, when administered parenterally, the compounds disclosed herein may be provided in a physiologically buffered aqueous solution containing about 0.1 to about 10 w / v% of the compound.
[0108] In some embodiments, the methods provided herein are i) Administering palsacricib or a pharmaceutically acceptable salt thereof to human subjects at a first dose of approximately 3 mg / day to approximately 20 mg / day for a first period of approximately 2 weeks to approximately 12 weeks. ii) In a human subject, pulsacricib or a pharmaceutically acceptable salt thereof (a) Approximately 2.5 mg / day or less or (b) Administering at a second dose of approximately 50 mg / week or less, The second dose is administered over the second period that follows the first period.
[0109] In some embodiments, each of the first doses is administered as a single, once-daily dose.
[0110] In some embodiments, each of the first doses is administered as a single, once-daily oral dose.
[0111] In some embodiments, the first dose is approximately 20 mg / day.
[0112] In some embodiments, the first dose is approximately 20 mg / day and is administered as a single, once-daily dose.
[0113] In some embodiments, the first dose is approximately 20 mg / day and is administered as a single, once-daily oral dose.
[0114] In some embodiments, the first dose is approximately 10 mg / day.
[0115] In some embodiments, the first dose is approximately 10 mg / day and is administered as a single, once-daily dose.
[0116] In some embodiments, the first dose is approximately 10 mg / day and is administered as a single, once-daily oral dose.
[0117] In some embodiments, the first dose is approximately 5 mg / day.
[0118] In some embodiments, the first dose is approximately 5 mg / day and is administered as a single, once-daily dose.
[0119] In some embodiments, the first dose is approximately 5 mg / day and is administered as a single, once-daily oral dose.
[0120] In some embodiments, the first period is approximately 3 to 11 weeks, for example, approximately 8 to 12 weeks, approximately 4 to 10 weeks, approximately 5 to 9 weeks, or approximately 8 to 9 weeks. In some embodiments, the first period is approximately 2 weeks, approximately 3 weeks, approximately 4 weeks, approximately 5 weeks, approximately 6 weeks, approximately 7 weeks, approximately 8 weeks, approximately 9 weeks, approximately 10 weeks, approximately 11 weeks, or approximately 12 weeks.
[0121] In some embodiments, the first period is approximately 8 to 9 weeks.
[0122] In some embodiments, the first period is approximately 8 weeks (or 56 days).
[0123] In some embodiments, the first period is approximately 9 weeks.
[0124] In some embodiments, the first dose is reduced during the first period.
[0125] In some embodiments, each of the second doses is administered as a single, once-daily dose.
[0126] In some embodiments, each of the second doses is administered as a single, once-weekly dose.
[0127] In some embodiments, each of the second doses is administered as a single, once-daily oral dose.
[0128] In some embodiments, each of the second doses is administered as a single, once-weekly oral dose.
[0129] In some embodiments, the second dose is approximately 5.0 mg / day or less, for example, approximately 5.0 mg / day, approximately 4.0 mg / day, approximately 3.0 mg / day, approximately 2.5 mg / day, approximately 2.0 mg / day, approximately 1.75 mg / day, approximately 1.5 mg / day, approximately 1.25 mg / day, or approximately 1.0 mg / day.
[0130] In some embodiments, the second dose is approximately 2.5 mg / day to approximately 7.5 mg / day.
[0131] In some embodiments, the second dose is approximately 3.0 mg / day to approximately 7.0 mg / day.
[0132] In some embodiments, the second dose is approximately 4.0 mg / day to approximately 6.0 mg / day.
[0133] In some embodiments, the second dose is approximately 2.5 mg / day.
[0134] In some embodiments, the second dose is approximately 2.5 mg / day and is administered as a single, once-daily dose.
[0135] In some embodiments, the second dose is approximately 2.5 mg / day and is administered as a single, once-daily oral dose.
[0136] As used herein, "approximately" when referring to measurable values such as volume, dosage, and duration means that it includes a variation of ±10%.
[0137] efficacy The anti-CD19 antibodies or their antigen-binding fragments described herein (e.g., tafacitamab) and palsacricib or pharmaceutically acceptable salts thereof can be used in combination to treat non-Hodgkin lymphoma in human subjects requiring treatment. In some embodiments, non-Hodgkin lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma. In some embodiments, non-Hodgkin lymphoma is relapsed / refractory diffuse large B-cell lymphoma.
[0138] Another embodiment includes a combination of the anti-CD19 antibody or its antigen-binding fragment (e.g., tafacitamab) described herein, and palsacricib or a pharmaceutically acceptable salt thereof, for use in the treatment of non-Hodgkin lymphoma. In some embodiments, non-Hodgkin lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma. In some embodiments, non-Hodgkin lymphoma is relapsed / refractory diffuse large B-cell lymphoma.
[0139] Another embodiment involves a combination of an anti-CD19 antibody or its antigen-binding fragment (e.g., tafacitamab) described herein and palsacricib or a pharmaceutically acceptable salt thereof in the manufacture of a drug for the treatment of non-Hodgkin lymphoma. In some embodiments, non-Hodgkin lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and mantle cell lymphoma. In some embodiments, non-Hodgkin lymphoma is relapsed / refractory diffuse large B-cell lymphoma.
[0140] A combination of the anti-CD19 antibody or its antigen-binding fragment described herein (e.g., tafacitamab) and palsacricib or a pharmaceutically acceptable salt thereof can be used to treat chronic lymphocytic leukemia in human subjects requiring treatment.
[0141] Another embodiment includes a combination of the anti-CD19 antibody or its antigen-binding fragment (e.g., tafacitamab) described herein, and palsacricib or a pharmaceutically acceptable salt thereof, for use in the treatment of chronic lymphocytic leukemia.
[0142] Another embodiment involves a combination of the anti-CD19 antibody or its antigen-binding fragment (e.g., tafacitamab) described herein and palsacricib or a pharmaceutically acceptable salt thereof in the manufacture of a drug for the treatment of chronic lymphocytic leukemia.
[0143] The anti-CD19 antibody or its antigen-binding fragment described herein (e.g., tafacitamab) and palsacricib or a pharmaceutically acceptable salt thereof can be used in combination to treat acute lymphoblastic leukemia in human subjects requiring treatment.
[0144] Another embodiment includes a combination of the anti-CD19 antibody or its antigen-binding fragment (e.g., tafacitamab) described herein, and palsacricib or a pharmaceutically acceptable salt thereof, for use in the treatment of acute lymphoblastic leukemia.
[0145] Another embodiment involves a combination of the anti-CD19 antibody or its antigen-binding fragment (e.g., tafacitamab) described herein and palsacricib or a pharmaceutically acceptable salt thereof in the manufacture of a drug for the treatment of acute lymphoblastic leukemia.
[0146] In some embodiments, pulsacricib or a pharmaceutically acceptable salt thereof is administered prior to the administration of an anti-CD19 antibody or its antigen-binding fragment.
[0147] In some embodiments, pulsacricib or a pharmaceutically acceptable salt thereof is administered after administration of an anti-CD19 antibody or its antigen-binding fragment.
[0148] In some embodiments, an anti-CD19 antibody or its antigen-binding fragment, and pulsacrisib or a pharmaceutically acceptable salt thereof are administered simultaneously or together.
[0149] The following are embodiments of the present invention. They should not be construed as limiting the scope of the present invention. [Examples]
[0150] The following examples are provided to better illustrate the claimed invention and are not intended to limit the scope of the invention. To the extent that specific materials are mentioned, they are for illustrative purposes only and are not intended to limit the invention. Those skilled in the art can develop equivalent means or reactants without exercising the capabilities of the invention and without departing from the scope of the invention.
[0151] Example 1: Cytotoxicity of the combination of tafacitamab and palsacricib The cytotoxicity of tafacitamab and palsacricib (INCB050465) alone and in combination will be tested in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), or acute lymphoblastic leukemia (ALL) cell lines selected from one of the following: Ramos (Burkitt lymphoma), MEC-1 (CLL), HG-3 (CLL), CII (CLL), Su-DHL6 (DLBCL), U2932 (DLBCL), JVM-2 (mantle cell lymphoma), and BALL-1 (ALL).
[0152] NHL, CLL, or ALL cells were pre-treated with 0.3, 1, 3, or 10 μM pulsacricib for 7 days (pulsacricib monotherapy group and tafacitamab and pulsacricib combination group). The tafacitamab monotherapy group was pre-treated with DMSO for the same period.
[0153] EasySep TM Using a human NK cell isolation kit (STEMCELL Technologies), NK cells were isolated from primary human PBMCs from multiple donors and frozen. The NK cells were thawed and cultured for 72 hours in medium supplemented with 2 IU / ml IL-2, either in or without 2 μM lenalidomide.
[0154] Seven days after pulsacricib treatment, NHL, CLL, or ALL cells are labeled with 10 μM CFSE and co-cultured with pre-treated NK cells for 4–16 hours in the presence or absence of lenalidomide, in the presence or absence of tafacitamab at various concentrations. The ratio of effector cells to target cells is 2:1. The cytotoxicity of tafacitamab alone is evaluated using the same procedure with NHL, CLL, or ALL cells not treated with pulsacricib. The dose of tafacitamab is 10 points at the highest concentration, starting from 15 μg / ml, at a 1:10 dilution. After 4–16 hours of incubation, cells are stained with DAPI or alternative cell viability dye and cytotoxicity is evaluated by flow cytometry. Data are presented as the percentage of dead cells and separated by NK donor.
[0155] The following controls were used: (i) NHL, CLL, or ALL cells + DMSO + NK cells, and (ii) NHL, CLL, or ALL cells + DMSO.
[0156] The combination index (CI) is calculated based on the isobol method (Ting-Chao Chou, 2010, Cancer Res. 70(2)). A CI < 1 is considered to indicate a synergistic effect.
[0157] Example 2: Combination study of tafacitamab and palsacricib in non-Hodgkin lymphoma subjects This is an open-label, multicenter clinical trial designed to evaluate the combination therapy of tafacitamab-parsacricib in patients with relapsed / refractory (R / R) diffuse large B-cell lymphoma (DLBCL).
[0158] Only participants whose biopsy has confirmed they have DLBCL, including one of the following NOS types (including DLBCL, GBC, and ABC), according to the 2016 WHO classification of lymphoid tumors, are eligible to participate in the trial.
[0159] Participants must have at least one two-dimensionally measurable lesion. At the time of screening, participants must have at least one lesion with a maximum transverse diameter of 1.5 cm or greater and a maximum vertical diameter of 1.0 cm or greater. The lesion must be confirmed to be PET-positive at the latest by the time of treatment.
[0160] Participants must have an ECOG (East Coast Cancer Group) performance status of 0-2.
[0161] Participants must meet the following screening criteria: a. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁻⁶ 9 / L (Unless it is secondary to myelopathic lesions due to DLBCL, as demonstrated by recent bone marrow aspiration and biopsy, in this case, absolute neutrophil count (ANC) ≥ 1.0 × 109 / L). b. Platelet count ≧75×10 9 / L (Unless it is secondary to myelopathies due to DLBCL, as demonstrated by recent bone marrow aspiration and biopsy, in this case, platelet count ≥ 50 × 10 9 / L). c. Total serum bilirubin < 1.5 × upper limit of normal (ULN) unless secondary to Gilbert's syndrome or hepatic involvement due to lymphoma is proven. Participants with Gilbert's syndrome or proven hepatic lesions due to lymphoma may be included if total bilirubin ≤ 5 × ULN. d. If liver lesions are confirmed, alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase ≤3×ULN or <5×ULN. e. Serum creatinine clearance must be 40 mL / min or greater, measured or calculated using the standard Cockcroff and Gold formulas.
[0162] Participants must have relapsed or refractory DLBCL.
[0163] Participants must have previously received at least one and up to three systemic therapies for the treatment of DLBCL. At least one of the previous treatment lines must have included CD20-targeted therapy (e.g., rituximab).
[0164] Participants must have failed autologous stem cell transplantation (ASCT), or, in the researchers' opinion, must not currently be eligible for high-dose chemotherapy (HDC) with subsequent ASCT for DLBCL participants.
[0165] Participants will be excluded from the test if they meet any of the following criteria. 1. Lymphomas of any other histological type according to the WHO 2016 classification of lymphoid neoplasms, e.g., primary mediastinal B-cell lymphoma (PMBL), Burkitt lymphoma, unclassifiable B-cell lymphoma with features intermediate between DLBCL and classical Hodgkin lymphoma (gray zone lymphoma); primary humoral lymphoma; primary cutaneous DLBCL (lower extremity type); intravascular B-cell lymphoma. 2. History of non-hematopoietic malignancies, excluding the following: a. A malignant tumor treated for curative purposes, with no evidence of active disease for more than two years prior to screening. b. Lentigo malignant melanoma or well-controlled non-melanoma skin cancer with no current evidence of disease. c. A cell tumor that is currently free of evidence of disease and has been appropriately treated. 3. Congestive heart failure requiring the use of continuous maintenance therapy for life-threatening ventricular arrhythmias. 4. Participants who fall under any of the following categories: Participants with a positive hepatitis aC test result (HCV antibody serological test) and a positive HCV RNA test result are eligible to participate. Participants with a positive serological test result must undergo local HCV RNA testing, and will only be eligible to participate if the HCV RNA test is negative. b. Known positive test results for chronic HBV infection (defined as HBsAg positive). Participants with latent or previous HBV infection (defined as HBsAg negative and total HBcAb positive) may participate only if they are willing to undergo continued DNA testing if HBV DNA is not detected (local test result). Antiviral prophylactic drugs may be administered according to facility guidelines. Participants with HBsAb protective titers after vaccination, or those who have not been vaccinated but have been cured of hepatitis B in the past, are eligible to participate. c. Known seropositive status or history of active HIV infection. d. Known active bacteria, viruses, fungi, mycobacteria or other infections at the time of screening. e. Involvement of known CNS lymphoma - current or past medical history. f. A history or evidence of clinically significant cardiovascular disease, CNS disease, and / or other systemic disease that, in the opinion of the principal investigator, would prevent the participant from participating in the study or impair their ability to give informed consent. g. A history or evidence of a rare genetic problem of galactose intolerance, pralactase deficiency, or glucose-galactose malabsorption. h. A history or evidence of interstitial lung disease. i. The patient must have received a live vaccine within 21 days prior to the trial treatment. j. Patients who have undergone major surgery within 30 days prior to signing the Informed Consent Form (ICF) (unless the participant has recovered by the time the ICF is signed). k. Anticancer drugs and / or experimental treatments within 14 days prior to the start of cycle 1. l. Gastrointestinal abnormalities, including those that prevent oral treatment, require intravenous nutritional support, or require prior surgical intervention affecting absorption. m. Pregnant or breastfeeding. Female participants who have discontinued breastfeeding are eligible to enroll in the study. Breastfeeding must be refrained from during the study period and for three months after the last dose of the study treatment. 5. Any restrictive drug, including potent CYP3A4 inhibitors or inducers, has been used or is scheduled to be used during the study period within 14 days prior to the date of administration of the study treatment or within 5 half-lives (whichever is longer). 6. Participants who meet the following criteria: a. CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy, or other lymphoma-specific therapy that has not been discontinued within 14 days prior to administration on day 1. b. In the researchers' opinion, the patient has not fully recovered from the harmful toxic effects of previous therapies. c. Prior treatment with CD19-targeted therapy (e.g., CD19-CAR-T therapy, bispecific and other CD19 mAbs including ADCs). d. Previously treated with a selective PI3Kδ or pan-PI3K inhibitor (e.g., idelalisib, copanlisib, duvelisib) and / or a Bruton's tyrosine kinase inhibitor (e.g., ibrutinib). e. A history of hypersensitivity to compounds with a similar biological or chemical composition to the excipients contained in tafacitamab, IMiD, and / or the investigational therapeutic formulation (citric acid monohydrate, polysorbate 20, sodium citrate dihydrate, and trehalose dihydrate). f. Participants have undergone an ASCT within three months prior to signing the ICF. Participants with a more recent history of ASCT must demonstrate complete hematological recovery before enrollment in the study. g. I have previously undergone allogeneic stem cell transplantation. h. Concomitant use of other anti-cancer or experimental therapies.
[0166] Tafacitamab administration plan: In the first three cycles of the trial, each cycle (cycles 1-3) consists of an intravenous infusion of tafacitamab 12 mg / kg on days 1, 8, 15, and 22 of the cycle. An additional loading dose is administered on day 4 of cycle 1. Subsequently, tafacitamab is administered by intravenous infusion every other week on days 1 and 15 of each 28-day cycle, repeated until discontinuation. If a reduction of the starting dose of tafacitamab by one dose level is necessary, the lower dose level is 9 mg / kg once weekly.
[0167] Pulsacrisib administration plan: Participants will self-administer oral palsacricib daily from day 1 to day 56, and then administer a dose of 2.5 mg once daily until discontinuation. The starting dose of palsacricib is 20 mg once daily from day 1 to day 56, followed by 2.5 mg once daily thereafter. If a dose reduction of palsacricib is necessary, depending on the current dose level, the lower dose levels from day 1 to day 56 may be as follows: 20 mg once daily can be reduced to 10 mg once daily, or 10 mg once daily can be reduced to 5 mg once daily.
[0168] The trial endpoints include: a. Incidence and severity of adverse events (TEAEs) and dose-limiting toxicity (DLTs) that occurred during treatment with the combination of tafacitamab and palsacricib. b. Pharmacokinetic (PK) analysis of tafacitamab as part of pulsacricib combination therapy. c. Objective response rate (ORR) reported by researchers according to lymphoma response criteria, d. Complete response rate (CRR) reported by researchers according to the lymphoma response criteria, e. Progression-free survival (PFS) for each researcher according to lymphoma response criteria, and f. Duration of response (DOR) is defined as the period from the first recorded complete response (CR) / complete metabolic response (CMR) or partial response (PR) / partial metabolic response (PMR) to the first recorded disease progression or death due to any cause, among participants who achieved CR / CMR or PR / PMR as determined by the IRC in accordance with the International Working Group guidelines, according to the response criteria for lymphoma.
[0169] Example 3: Combination study of tafacitamab and palsacricib in subjects with relapsed / refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. This is an open-label, multicenter clinical trial designed to evaluate the combination therapy of tafacitamab-parsacricib in subjects with relapsed / refractory (R / R) non-Hodgkin lymphoma or chronic lymphocytic leukemia.
[0170] Participants have R / RB cell malignancies, including R / R diffuse large B-cell lymphoma (DLBCL), R / R mantle cell lymphoma (MCL), R / R follicular lymphoma (FL), R / R marginal zone lymphoma (MZL), or R / R chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL).
[0171] Participants are eligible to participate in this clinical trial only if all of the following criteria are met. 1. Males and females who are 18 years of age or older at the time of consent. 2. Ability to understand, sign, and follow all examination visits and procedures in writing regarding the ICF. 3. Histologically confirmed R / RB cell malignancies of the following types: a. Cohort 1: DLBCL without specific designation, T-cell / histiocyte-rich large B-cell lymphoma, Epstein-Barr virus-positive DLBCL in elderly patients, grade 3b FL, MYC, and high-grade B-cell lymphomas (double-matched or triple-matched lymphomas) with BCL2 and / or BCL6 rearrangements, and histological conversion from early diagnosis to DLBCL in low-grade lymphomas (FL, MZL, CLL, etc.). b. Cohort 2: MCLs with recorded overexpression of either cyclin D1 or t(11;14) c. Cohort 3: FL grades 1, 2, and 3a d. Cohort 4: MZL (including extranodal, nodal, and splenic subtypes) e. Cohort 5: CLL or SLL 4. You are willing to undergo any biopsies required for the examination, including lymph node biopsy or tissue biopsy by incision, excision, or core needle biopsy (or lymph node or tissue from an archive of the most recent biopsy), and, if necessary, bone marrow biopsy / aspiration. 5. You have received at least two previous systemic treatment plans, such as the following: a. Cohorts 1 and 2 (DLBCL, MCL): Must have previously been treated with at least one prior chemoimmunotherapy regimen including an anti-CD20 antibody. This includes treatments such as chemotherapy in combination with rituximab or obinutuzumab, with or without maintenance of rituximab or obinutuzumab. Note: At least six doses of anti-CD20 chemoimmunotherapy must have been administered in the prior treatment. b. Cohorts 3 and 4 (FL, MZL): Must have previously been treated with at least one prior chemoimmunotherapy or immunotherapy regimen containing an anti-CD20 antibody. This includes treatments such as rituximab or obinutuzumab monotherapy, or chemotherapy in combination with rituximab or obinutuzumab, with or without maintenance of rituximab or obinutuzumab. Note: At least six doses of anti-CD20 immunotherapy must have been administered in the prior treatment. c. Cohort 5 (CLL / SLL): Must have been previously treated with at least one prior systemic therapy regimen, including a BTK inhibitor regimen or a chemoimmunotherapy regimen containing an anti-CD20 antibody. 6. Relapsed, progressive, or refractory NHL or CLL: a. Relapsed: Progressive disease (PD) following a complete response (CR) to previous treatment. b. Progressive: PD after a partial response (PR) or stable disease response to previous treatment. c. Refractory: Achieved less than a partial response (PR) in the previous treatment, or achieved a complete response (CR) or PR that lasted for less than 6 months prior to disease progression (PD). 7. For cohorts 1-4 and cohort 5 / SLL: measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of one or more lesions with a maximum transverse diameter of 1.5 cm or more and a maximum vertical diameter of 1.0 cm or more as evaluated by CT or MRI). 8.ECOG activity index 0~2. 9. Average life expectancy > 3 months. 10.LVEF (left ventricular ejection fraction) ≥50%. 11. The screening test results were as follows: a. Hemoglobin level ≥ 8 g / dL (except in cases secondary to bone marrow involvement due to NHL / CLL, as evidenced by recent bone marrow aspiration and biopsy). b. ANC ≥ 1.5 × 10⁹ / L (except in cases secondary to bone marrow involvement due to NHL / CLL, as evidenced by recent bone marrow aspiration and biopsy). c. Platelet count ≥ 75 × 10⁹ / L (except in cases secondary to bone marrow involvement due to NHL / CLL, as evidenced by recent bone marrow aspiration and biopsy). d. Total serum bilirubin level ≤1.5 × ULN or ≤5 × ULN (if liver damage due to Gilbert's syndrome or lymphoma is demonstrated) e. ALT, AST, and alkaline phosphatase levels are 3×ULN or less, or 5×ULN or less if liver damage is confirmed. f. Serum creatinine clearance ≥ 50 mL / min, measured or calculated using the standard Cockcroft and Gault formula (Cockcroft and Gault 1976). 12. The intention to avoid becoming pregnant with or fathering a child, based on the following criteria. a. Male participants who may have children must agree to take appropriate precautions from screening until 6 months after the last dose of the investigational treatment to avoid becoming fathers of children (with at least 99% certainty), and must refrain from donating sperm during this period. b. Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to take appropriate precautions (with at least 99% certainty) to avoid pregnancy from screening until 90 days (or 180 days if required by local regulations) after the last dose of the investigational treatment. They must also agree to undergo regular urine pregnancy tests throughout the investigational treatment period. Furthermore, they must refrain from breastfeeding and egg donation during the investigational treatment period and for three months after the last dose of the investigational treatment. c. Female participants who are unable to have children (i.e., surgically infertile due to hysterectomy and / or bilateral oophorectomy, or amenorrhea for 12 months or more, and at least 50 years of age) are eligible. Female participants who have been amenorrhea for at least 12 months due to the effects of chemotherapy / radiotherapy are considered to be of potential pregnancy and must agree to use appropriate contraception.
[0172] Participants will be excluded from the test if they meet any of the following criteria. 1. Lymphomas of any other histological type according to the WHO 2016 classification of lymphoid neoplasms, such as primary mediastinal B-cell lymphoma, Burkitt lymphoma, unclassifiable B-cell lymphoma with features intermediate between DLBCL and classical Hodgkin lymphoma (gray zone lymphoma); primary humoral lymphoma; primary cutaneous DLBCL (lower extremity type); intravascular B-cell lymphoma. 2. History or evidence of CNS lymphoma (primary and secondary). 3. Any anti-cancer and / or investigational therapies (e.g., chemotherapy, radiotherapy, surgery, immunotherapy, biological therapy, hormone therapy, or tumor embolization) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of the investigational treatment (C1D1). 4. Inadequate recovery (>Grade 1) from toxicity and / or complications from major surgery prior to C1D1. 5. Any prohibited substance, including potent CYP3A4 inhibitors or inducers, has been used or is scheduled to be used during the study within 14 days prior to C1D1 or within 5 half-lives (whichever is longer). 6. Allogeneic stem cell transplantation within the past 6 months prior to C1D1, or ASCT within the past 3 months. 7. Prior treatment with CD19-targeted therapy (e.g., CD19-CAR-T therapy, bispecific and other CD19 mAbs including antibody-drug conjugates) or PI3K inhibitors. 8. Treatment with corticosteroids at doses exceeding the physiological dose (prednisone equivalent dose > 10 mg / day) within 7 days of the start of the study treatment. 9. Clinically significant cardiac disease occurring within 6 months of C1D1, including unstable angina, acute myocardial infarction, congestive heart failure of New York Heart Association class II–IV, uncontrolled arrhythmias, and / or cardiac conduction disorders. 10. Clinically significant, uncontrolled concomitant medical conditions, including but not limited to, kidney, liver, blood, GI, endocrine, lung, neurological, cerebral, or psychiatric disorders. 11. Other current or previous malignancies within three years of trial enrollment, excluding cured basal cell or squamous cell carcinoma, superficial bladder cancer, prostatic intraepithelial neoplasia, or cervical intraepithelial neoplasia. 12. Active graft-versus-host disease. 13. A history of stroke or intracranial hemorrhage within 6 months of C1D1. 14. A chronic or currently active infection requiring treatment with systemic antibiotics, antifungal agents, or antiviral agents within 30 days of C1D1. 15. Any of the following: Participants with a positive hepatitis aC test result (HCV antibody serological test) and a positive HCV RNA test result are eligible to participate. Participants with a positive serological test result must undergo local HCV RNA testing, and will only be eligible to participate if the HCV RNA test is negative. b. Known positive test results for chronic HBV infection (defined as HBsAg positive). Participants with latent or previous HBV infection (defined as HBsAg negative and total HBcAb positive) may participate only if they are willing to undergo continued DNA testing if HBV DNA is not detected (local test result). Antiviral prophylactic drugs may be administered according to facility guidelines. Participants with HBsAb protective titers after vaccination, or those who have not been vaccinated but have been cured of hepatitis B in the past, are eligible to participate. c. Known seropositive status or history of active HIV infection. 16. Inability to swallow and retain oral medications, malabsorption syndrome, disease significantly affecting GI function, total gastrectomy or small bowel resection, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. 17. A history of hypersensitivity to compounds with a similar biological or chemical composition to the excipients contained in tafacitamab, palsacricib, and / or the investigational therapeutic formulation. 18. A history of severe allergic reactions, including anaphylaxis and toxic epidermal necrolysis. 19. A history or evidence of interstitial lung disease. 20. C1D1: Have you received a live vaccine within 30 days prior to this date, or is there a need for such a vaccine during treatment? 21. I am currently pregnant or breastfeeding. 22. Conditions, at the discretion of the principal investigator, that prevent full participation in the trial, pose a significant risk to the participant, or interfere with the interpretation of trial data, including the administration of the investigational drug and participation in necessary trial visits.
[0173] Tafacitamab administration plan: In the first three cycles of the trial, each cycle (cycles 1-3) consists of an intravenous infusion of tafacitamab 12 mg / kg on days 1, 8, 15, and 22 of the cycle. Thereafter, tafacitamab is administered by intravenous infusion on days 1 and 15 of each 28-day cycle, repeated every other week until discontinuation.
[0174] Pulsacrisib administration plan: Participants will self-administer oral palsacricib daily for 8 weeks, followed by a dose of 2.5 mg once daily until discontinuation. The starting dose of palsacricib is 20 mg once daily for 8 weeks, followed by 2.5 mg once daily.
[0175] The trial endpoints include: a. Incidence and severity of TEAEs, and incidence of DLTs. b. ORR, defined as the percentage of participants who showed the best response (CR / CMR) or PR / PMR for each researcher assessment. c. PK parameters of tafacitamab when administered in combination with parsacrisib. trough (i.e., before administration), C max , t max , C min and AUC t This is summarized by descriptive statistics. d. CRR is defined as the percentage of participants who showed the best response in CR / CMR for each researcher's assessment. e. For participants who have achieved CR / CMR or PR / PMR, the Date of Recovery (DOR) is defined as the period from the first documented CR / CMR or PR / PMR to the first documented date of disease progression or death from any cause, whichever occurs first. f. PFS is defined as the period from the first dose of the study treatment to the first documented disease progression or death from any cause, whichever occurs first. g. Overall survival (OS), defined as the time from the first dose of the investigational treatment to death from any cause. h. The percentage of participants who expressed ADA (anti-drug antibody) specific to tafacitamab. i. Analysis of the dynamic composition of cytokines and immune cell populations and subpopulations in peripheral blood using proteomics and flow cytometry. Analysis of the tumor microenvironment using j.RNA expression signatures. k. Analysis of CD19 and other mutations in peripheral blood using next-generation sequencing (NGS). l. Analysis of RNA expression profiles, RNA splicing patterns, and DNA mutations / indels / single nucleotide polymorphisms. Evaluation of MRD (minimally invasive residual disease) after response by polymerase chain reaction or NGS.
[0176] Example 4: In vitro analysis of cytotoxicity of the combination of tafacitamab and palsacrisib The cytotoxicity of tafacitamab and palsacricib (INCB050465), both alone and in combination, was tested in the following cell lines: MEC-1 (CLL), MEC-2 (CLL), JVM-2 (mantle cell lymphoma), WSU-NHL, Pfeiffer, Su-DHL4, and Su-DHL6.
[0177] Target cells were pre-treated with pulsacricib at various doses ranging from 0.3 to 20 μM for 7 days (pulsacricib monotherapy group and tafacitamab and pulsacricib combination group). The tafacitamab monotherapy group was pre-treated with DMSO for the same period.
[0178] EasySep TM Using a human NK cell isolation kit (STEMCELL Technologies), NK cells were isolated from primary human PBMCs from multiple donors and frozen. The NK cells were thawed and cultured overnight in medium supplemented with 2 IU / ml of IL-2 (Peprotech) 24 hours before the ADCC assay.
[0179] The following controls were used in all experiments: (i) target cells + NK cells without antibody, (ii) target cells + NK cells + huIgG1 isotype control antibody, and (iii) target cells only.
[0180] After 7 days of pulsacricib treatment, target cells were harvested and subjected to 0.1 μM CellTrace TM NK cells were labeled with Far Red Cell Proliferation dye (ThermoFisher C34564) and co-cultured with tafacitamab for 4 hours in the presence of various concentrations of tafacitamab. The ratio of effector cells to target cells was 2:1. The growth inhibitory effect of pulsacrisib on target cells was included by adjusting the E:T ratio of the inhibitor-treated cells.
[0181] The cytotoxicity of tafacitamab alone was evaluated in DMSO-treated cells using the same procedure. The tafacitamab dose was 10 points at the highest concentration of 1:10 dilution, starting from 1 μg / ml. After 4 hours of incubation, cells were stained with Zombie Violet fixable cell viability dye (Biolegend423114) and cytotoxicity was assessed by flow cytometry. Data were expressed as the percentage of dead target cells minus the percentage of cell death from the "target cells only" well to account for background. The NK cells used were from two healthy human donors.
[0182] Tafacitamab demonstrated dose-dependent ADCC activity in Mec1 and JVM2 cells. The combination of tafacitamab and palsacricib showed additional ADCC activity in JVM2 cells compared to tafacitamab and palsacricib monotherapy, but not in Mec1 cells. Data from two separately conducted experiments were analyzed to assess the potential synergistic activity of tafacitamab and palsacricib in JVM2 cells. In both experiments, the selected doses of tafacitamab and palsacricib showed synergistic effects in JVM2 cells, as indicated by a synergy score > 10. See Figures 1A–1B for evaluation of synergistic effects using the Bliss synergy model in each experiment. Synergy scores were calculated using SynergyFinder2.0 (https: / / synergyfinder.fimm.fi). A synergy score > 10 is considered synergistic.
[0183] In addition to ADCC cytotoxicity, the effects of tafacitamab and palsacricib on cell proliferation were also evaluated by treating target cells with matrix administration of tafacitamab and palsacricib in the absence of NK cells. Proliferation was assessed at 24, 48, and 72 hours by adding 100 μl of Cell titer Glo to wells containing two 100 μl of treated cells each. Data were expressed as RLU, proportional to cell proliferation. Pfeiffer cells and WSU-NHL cells were sensitive to palsacricib treatment, and their proliferation was inhibited by palsacricib treatment in a time- and dose-dependent manner. Mec2 cells and JVM2 cells were sensitive to tafacitamab treatment, and their proliferation was inhibited by tafacitamab in a time- and dose-dependent manner. SuDHL4 cells and SuDHL6 cells were not sensitive to either tafacitamab or palsacricib treatment. No synergistic effect was observed with the combination of tafacitamab and palsacricib.
[0184] Example 5: In vivo efficacy experiment of a combination of anti-CD19 antibody and pulsacrisib in a mouse lymphoma model 5 × 105 Individual A20 mouse lymphoma cells were subcutaneously inoculated, and flank tumors were formed. The tumors were approximately 100 mm in size. 3 When the mice reached a certain stage, they were randomly divided into four groups and administered (N=10 mice / group). The treatment groups were as follows: (1) vehicle (5% dimethylacetylide + 95% methylcellulose) - administered orally twice daily, (2) mouse anti-CD19 antibody (Absolute Antibody 12014B35) - 150 mg administered intraperitoneally once weekly, (3) palsacricib (INCB050465) - 3 mg / kg administered orally twice daily, (4) mouse anti-CD19 antibody + palsacricib.
[0185] Tumor volume was measured twice a week. The experiment aimed for an average tumor volume of 2000 mm³ in each group. 3 The study was terminated when the target was reached. All doses were tolerable when assessed by body weight. The tumor growth inhibition percentage (TGI%) was calculated as [1 - (mean tumor volume of the study group) / (mean tumor volume of the vehicle group)] × 100. Tumor growth delay (TGD) was determined by the (approximate) number of days required after the end of administration for the mean tumor volume of the treatment group to reach the final mean tumor volume of the vehicle group.
[0186] The effect of combination therapy with anti-CD19 antibody and pulsacricib on TGI was greater than the effect expected based on monotherapy activity, demonstrating a synergistic effect associated with the combination. See Figure 2. Only the anti-CD19 antibody + pulsacricib combination treatment group showed a statistically significant difference in TGI compared to the vehicle treatment group. See Table 1. No statistically significant difference was found between the combination group and the pulsacricib group in TGI. [Table 1]
[0187] The combination therapy of an anti-CD19 antibody and pulsacrisib was more effective against TGD than expected based on monotherapy activity, demonstrating a synergistic effect associated with the combination. See Figure 3 and Table 2. [Table 2]
[0188] Other Embodiments The present invention has been described above with a detailed description thereof, but the above description is intended to illustrate, and not to limit, the scope of the present invention as defined by the appended claims. Other embodiments, advantages and modifications are within the scope of the following claims.
Claims
1. A medicament for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, or acute lymphocytic leukemia in a human subject in need thereof, the medicament being used in combination with 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one, or a pharma- ceutical acceptable salt thereof, the medicament comprising an antibody that binds to human CD19; the antibody comprises a variable heavy (VH) domain comprising a VH complementarity determining region (CDR) 1, a VH CDR2 and a VH CDR3, wherein: VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO:6), VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO:7), VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO:8), The antibody comprises a variable light (VL) domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 9), VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO: 10), VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO: 11), Medicine.
2. The pharmaceutical composition of claim 1, wherein the VH domain comprises the amino acid sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS (sequence number 4), and the VL domain comprises the amino acid sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (sequence number 5).
3. The pharmaceutical of claim 1, wherein the antibody comprises a heavy chain and a light chain, the heavy chain comprising the amino acid sequence shown in SEQ ID NO:2, and the light chain comprising the amino acid sequence shown in SEQ ID NO:
3.
4. The method according to any one of claims 1 to 3, wherein the human subject has non-Hodgkin's lymphoma.
5. The pharmaceutical composition according to claim 4, wherein the non-Hodgkin's lymphoma is diffuse large B-cell lymphoma.
6. The pharmaceutical composition according to claim 5, wherein the diffuse large B-cell lymphoma is relapsed / refractory diffuse large B-cell lymphoma.
7. The pharmaceutical composition according to claim 4, wherein the non-Hodgkin's lymphoma is follicular lymphoma.
8. The pharmaceutical composition according to claim 4, wherein the non-Hodgkin's lymphoma is small lymphocytic lymphoma.
9. The pharmaceutical composition according to claim 4, wherein the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue lymphoma.
10. The pharmaceutical composition according to claim 4, wherein the non-Hodgkin's lymphoma is marginal zone lymphoma.
11. The pharmaceutical composition according to claim 4, wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma.
12. The pharmaceutical composition according to claim 4, wherein the non-Hodgkin's lymphoma is mantle cell lymphoma.
13. The method according to any one of claims 1 to 3, wherein the human subject has chronic lymphocytic leukemia.
14. The method according to any one of claims 1 to 3, wherein the human subject has acute lymphoblastic leukemia.
15. The method according to any one of claims 1 to 14, wherein the antibody is administered intravenously.
16. The method according to any one of claims 1 to 14, wherein the antibody is administered intravenously at a dose of 9 mg / kg or 12 mg / kg.
17. The method of any one of claims 1 to 14, wherein the antibody is administered intravenously at a dose of 9 mg / kg or 12 mg / kg at least once every two weeks.
18. The antibody is administered according to the following schedule: Days 1, 4, 8, 15, and 22 of the first 28-day cycle; days 1, 8, 15, and 22 of the second 28-day cycle; Days 1, 8, 15, and 22 of the third 28-day cycle; and Days 1 and 15 of the fourth 28-day cycle and days 1 and 15 of any additional 28-day cycles thereafter The medicament according to any one of claims 1 to 14, which is administered intravenously at a dose of 12 mg / kg according to the formula:
19. The pharmaceutical composition according to any one of claims 1 to 18, wherein 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one or a pharma- ceutically acceptable salt thereof is administered orally.
20. 19. The pharmaceutical composition of any one of claims 1 to 18, wherein 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one or a pharma- ceutically acceptable salt thereof is orally administered at a dose of 1 mg, 2.5 mg, 5 mg, 10 mg or 20 mg.
21. The pharmaceutical composition according to any one of claims 1 to 18, wherein 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one or a pharma- ceutically acceptable salt thereof is orally administered once daily at a dose of 1 mg, 2.5 mg, 5 mg, 10 mg or 20 mg.
22. 19. The pharmaceutical composition of any one of claims 1 to 18, wherein 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one or a pharma- ceutically acceptable salt thereof is orally administered once daily at a dose of 20 mg on days 1 to 56, and at a dose of 2.5 mg thereafter.
23. The antibody is administered according to the following schedule: Days 1, 4, 8, 15, and 22 of the first 28-day cycle; days 1, 8, 15, and 22 of the second 28-day cycle; Days 1, 8, 15, and 22 of the third 28-day cycle; and Days 1 and 15 of the fourth 28-day cycle and days 1 and 15 of any additional 28-day cycles thereafter was administered intravenously at a dose of 12 mg / kg according to 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one or a pharma- ceutically acceptable salt thereof administered orally at a dose of 20 mg once daily on days 1 through 56, and at a dose of 2.5 mg once daily thereafter; The pharmaceutical composition according to any one of claims 1 to 14.
